HYFTNasdaqPharmaceutical PreparationsFiscal year ends April 30

MindWalk Holdings Corp.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 20-F on Jul 23, 2026

$1.32+0.01 (+0.76%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Jul 31, 2026

MindWalk reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in MindWalk's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in MindWalk's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-5 reverse split on Nov 23, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is HYFT.

Revenue growth43.4% · median -62.8%

Gross margin60.8% · median 43.8%

Company	Revenue	Growth
ZYME	$37.13M	-69.8%
JAGX	$27.82M	+135.5%
CELU	$18.97M	-62.8%
HYFT	C$16.23M	+43.4%
BHST	–	–
IMMP	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: April 30
Held by institutions: 9.3%
Auditor: Grant Thornton
SEC CIK: 1715925

Advertisement
300 × 250